수의용 통증 관리 시장 보고서 : 제품 유형별, 동물 유형별, 용도별, 최종사용자별, 지역별(2026-2034년)

The global veterinary pain management market size reached USD 1.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.51% during 2026-2034. There are several factors that are driving the market, which include the rising number of pet parents, various regulatory approvals, and increasing prevalence of chronic diseases such as arthritis, cancer, joint pain, and post-surgical pain.

Veterinary Pain Management Market Analysis:

• Major Market Drivers: The market is experiencing moderate growth because of the increasing awareness about animal welfare and technological advancements.
• Key Market Trends: The growing number of pet parents and various regulatory approvals are key market trends.
• Geographical Trends: North America exhibits a clear dominance, accounting for the biggest market share owing to the presence of state-of-the-art hospitals and clinics equipped with modern diagnostic and treatment technologies.
• Competitive Landscape: Top market players in the veterinary pain management industry are Alivira Animal Health Limited, Animalcare Group Plc, Boehringer Ingelheim Animal Health USA Inc, Ceva Sante Animale, Chanelle Pharma, Dechra Pharmaceuticals, Elanco, Merck & Co., Inc, Norbrook, Vetoquinol Group, and Zoetis Services LLC, among many others.
• Challenges and Opportunities: Regulatory hurdles represent a key market challenge. Nonetheless, the expansion into emerging markets, along with the increasing focus on telemedicine, is anticipated to overcome these challenges and offer recent market opportunities.

Veterinary Pain Management Market Trends:

Rising Number of Pet Parents

The increasing number of pet parents is catalyzing the demand for veterinary care, including pain management. Pet parents view their pets as a part of their family, leading to higher spending on health services to ensure their pets' well-being. There is a rise in the need for veterinary pain management services, such as pain relief medications, physiotherapy, and post-surgical treatments. As pet parents are becoming more aware of their pets' health issues, they are willing to invest in advanced veterinary treatments including preventive and therapeutic measures for chronic and acute pain. This shift in consumer behavior, coupled with inflating income levels of individuals, is representing one of the major veterinary pain management market growth factors. According to Dogster, the pet cat population is anticipated to reach 4.89 million by 2026 in India.

Various Regulatory Approvals

On 2 May 2023, Elanco Animal Health Incorporated announced that the U.S. Department of Agriculture (USDA) provided a conditional license for the first Canine Parvovirus Monoclonal Antibody. This was the first and only approved therapeutic solution proven to treat canine parvovirus, one of the most contagious and deadly viruses a dog can contract with a 91% mortality rate if not treated with supportive care. In addition, regulatory approvals play a critical role in the veterinary pain management market by ensuring that drugs and therapies are safe, effective, and tailored for use in animals. Key regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are overseeing the approval process for veterinary pain management products while ensuring that these treatments meet stringent safety and efficacy standards.

Increasing Prevalence of Chronic Diseases

Rising incidences of chronic diseases such as arthritis, cancer, and degenerative joint diseases are offering a favorable veterinary pain management market outlook. These illnesses, which cause severe discomfort and pain, are more common in older pets, particularly in dogs and cats. Chronic illnesses also affect livestock and equine animals that require pain management. Furthermore, the availability of more advanced diagnostic tools enables early detection of these diseases and allowing veterinarians to prescribe pain management solutions more effectively. Additionally, businesses are creating treatments to help lessen the suffering that these chronic illnesses cause in animals. For example, on November 13, 2023, Krka announced the release of Robexera, the first generic version of robenacoxib intended to relieve pain and inflammation in dogs undergoing soft tissue surgery and chronic osteoarthritis (OA).

Veterinary Pain Management Market Segmentation:

Breakup by Product:

• Drugs
  • NSAIDs
  • Anesthetics
  • Opioids
  • Other Drugs
• Devices
  • Laser Therapy
  • Electromagnetic Therapy

Drugs account for the majority of the market share

Drugs are used to treat pain and inflammation in pets and are widely prescribed due to their effectiveness and relatively mild side effect profiles. Veterinarians and pet parents are recognizing the importance of effective pain management in improving the quality of life for animals. This awareness is leading to a high demand for pain relief medications. As more pets experience chronic conditions, the demand for effective pain management solutions continues to rise. This trend drives the consumption of pain-relief medications.

Breakup by Animal Type:

• Companion
• Livestock

Pets like dogs and cats as well as smaller animals like rabbits and guinea pigs are considered companion animals. Pet parents are more likely to look for ways to relieve their furry friends' pain. Chronic diseases including cancer, arthritis, and dental discomfort are common in aging pets, making appropriate pain management techniques necessary. The prevalence of these conditions drives the consumption of NSAIDs, opioids, and other pain management drugs.

Livestock animals comprise pigs, poultry, sheep, and cattle. Livestock is an important source of income for farmers and economies. To maintain livestock welfare and maximize production, it is imperative to provide appropriate pain treatment to ensure the health and productivity of these animals. Enough pain treatment for animals having surgery or suffering from illnesses is becoming more and more important. Equine patients frequently experience ailments like mastitis in dairy cows, lameness in sheep, and pain following surgery, necessitating the implementation of efficient pain treatment techniques.

Breakup by Application:

• Osteoarthritis and Joint Pain
• Postoperative Pain
• Cancer
• Others

Osteoarthritis and joint pain represent the leading market segment

The rising prevalence of osteoarthritis and joint pain among animals is bolstering the market growth. As pets age, they become more susceptible to osteoarthritis and other joint-related issues. This is particularly frequent in larger dog breeds, which tend to develop joint problems earlier in life. In addition, the high prevalence of obesity in pets is a factor in joint stress and osteoarthritis development. Overweight pets are more likely to experience joint pain, which is leading to a positive veterinary pain management market forecast.

Breakup by End User:

• Hospitals and Clinics
• Others

Hospitals and clinics exhibit a clear dominance in the market

The main healthcare providers for pets and animals are veterinary hospitals and clinics as they provide a variety of services like diagnosis, treatment, and pain management. They can address a variety of health conditions including pain management efficiently. These clinics also employ support personnel who have received specific training in pain treatment, as well as licensed veterinarians. This knowledge guarantees that animals receive proper evaluations, diagnoses, and treatments catered to their individual requirements. Many pet parents regularly bring their pets to clinics and hospitals for check-ups, vaccinations, and other preventive care.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest veterinary pain management market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for veterinary pain management.

North America, especially the United States and Canada, has one of the highest rates of pet parents. As per Forbes, as of 2024, around 66% of households in the United States own a pet. Moreover, cutting-edge veterinary hospitals and clinics with advanced diagnostic and therapeutic equipment are present throughout the North American region. These facilities allow veterinarians to recognize and treat animal pain accurately. Furthermore, there is a strong cultural emphasis on animal welfare in North America, leading to greater awareness among pet parents and veterinarians about the importance of pain management. All these factors are providing veterinary pain management market overview in the region.

Competitive Landscape:

Leading companies are allocating resources for research and development (R&D) activities aimed at creating novel and sophisticated pain management commodities such as dietary supplements, painkillers, and therapeutic interventions. For better animal care, they are introducing targeted medicines such monoclonal antibodies. As to confirm the effectiveness and safety of their products, some businesses are carrying out clinical trials, which aid in receiving regulatory clearances and increasing consumer acceptance. Moreover, companies are concentrating on joint ventures and acquisitions to broaden their range of products across diverse regions. For example, on 2 May 2023, Virbac acquired its distributor in the Czech Republic and Slovakia. This new Virbac subsidiary will enable the company to respond more widely and quickly to the health needs of animals in the Czech Republic and Slovakia.

The report provides a comprehensive analysis of the competitive landscape in the global veterinary pain management market with detailed profiles of all major companies, including:

• Alivira Animal Health Limited
• Animalcare Group Plc
• Boehringer Ingelheim Animal Health USA Inc
• Ceva Sante Animale
• Chanelle Pharma
• Dechra Pharmaceuticals
• Elanco
• Merck & Co., Inc
• Norbrook
• Vetoquinol Group
• Zoetis Services LLC

Frequently Asked Questions About the Veterinary Pain Management Market Report

1.How big is the global veterinary pain management market?

2.What is the expected growth rate of the global veterinary pain management market during 2026-2034?

3.What are the key factors driving the global veterinary pain management market?

4.What has been the impact of COVID-19 on the global veterinary pain management market?

5.What is the breakup of the global veterinary pain management market based on the product?

6.What is the breakup of the global veterinary pain management market based on the application?

7.What is the breakup of the global veterinary pain management market based on the end user?

8.What are the key regions in the global veterinary pain management market?

9.Who are the key players/companies in the global veterinary pain management market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Veterinary Pain Management Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Drugs
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 NSAIDs
    • 6.1.2.2 Anesthetics
    • 6.1.2.3 Opioids
    • 6.1.2.4 Other Drugs
  • 6.1.3 Market Forecast
• 6.2 Devices
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Laser Therapy
    • 6.2.2.2 Electromagnetic Therapy
  • 6.2.3 Market Forecast

7 Market Breakup by Animal Type

• 7.1 Companion
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Livestock
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Application

• 8.1 Osteoarthritis and Joint Pain
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Postoperative Pain
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Cancer
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospitals and Clinics
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Others
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Alivira Animal Health Limited
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Animalcare Group Plc
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Boehringer Ingelheim Animal Health USA Inc
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Ceva Sante Animale
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Chanelle Pharma
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Dechra Pharmaceuticals
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
  • 15.3.7 Elanco
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Merck & Co., Inc
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Norbrook
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Vetoquinol Group
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
  • 15.3.11 Zoetis Services LLC
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis